Critical Path Institute -Translational Therapeutics Accelerator (TRxA)
Ends on 19 March 2025
The Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) is a global drug discovery and development program focused on supporting academic scientists in defining optimal strategies for advancing new, cutting-edge therapeutics from the lab to patients.
To be eligible, investigators need to hold a faculty appointment at a university or non-profit research institution (anywhere in the world), and intellectual property (IP) associated directly to the project cannot yet have been exclusively optioned or out-licensed.